{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:05Z","timestamp":1761101045045,"version":"3.44.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jinf.2010.08.010","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T06:25:47Z","timestamp":1284359147000},"page":"476-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)"],"prefix":"10.1016","volume":"61","author":[{"given":"David J.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2010.08.010_bib1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1469-0691.2000.00185.x","article-title":"Ketolides \u2013 telithromycin, an example of a new class of antibacterial agents","volume":"6","author":"Bryskier","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2010.08.010_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/dkg123","article-title":"Drugs of the 21st century: telithromycin (HMR 3647)\u2013the first ketolide","volume":"51","author":"Ackermann","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2010.08.010_bib3","unstructured":"McGhee P, Nagai K, Appelbaum PC. Activity of CEM-101 compared to other agents agianst macrolide-susceptible and resistant streptococci. In: 48th ICAAC, October 25\u201328, 2008. Washington DC, USA: Antimicrob. Agents Chemother., 2008. [abstract F1-3974]."},{"key":"10.1016\/j.jinf.2010.08.010_bib4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/AAC.01123-09","article-title":"In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms","volume":"54","author":"McGhee","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2010.08.010_bib5","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1128\/AAC.01662-09","article-title":"CEM-101 activity against Gram-positive organisms","volume":"54","author":"Woosley","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2010.08.010_bib6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2010.01.026","article-title":"Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates","volume":"35","author":"Farrell","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2010.08.010_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.diagmicrobio.2009.10.013","article-title":"CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria","volume":"66","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2010.08.010_bib8","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.00090-09","article-title":"Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101","volume":"53","author":"Waites","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"year":"2009","series-title":"M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.jinf.2010.08.010_bib9"},{"year":"2010","series-title":"M100-S20. Performance standards for antimicrobial susceptibility testing: 20th informational supplement","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.jinf.2010.08.010_bib10"},{"key":"10.1016\/j.jinf.2010.08.010_bib11","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1128\/JCM.01992-09","article-title":"MIC quality control guidelines and disk diffusion test optimization for CEM-101, a novel fluoroketolide","volume":"48","author":"Jones","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"Suppl. 2","key":"10.1016\/j.jinf.2010.08.010_bib12","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2010.08.010_bib13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1086\/528996","article-title":"Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005","volume":"197","author":"Moore","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2010.08.010_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.inf.0000253059.84602.c3","article-title":"Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States","volume":"26","author":"Farrell","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2010.08.010_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/INF.0b013e31819e3f7a","article-title":"Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates","volume":"28","author":"Li","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2010.08.010_bib16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1473-3099(09)70133-1","article-title":"Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia","volume":"9","author":"Hidron","year":"2009","journal-title":"Lancet Infect Dis"},{"year":"1998","series-title":"Guidance for industry: uncomplicated skin and skin structure infections\u2013Developing antimicrobial drugs for therapy [online]","author":"[FDA] FaDA","key":"10.1016\/j.jinf.2010.08.010_bib17"},{"key":"10.1016\/j.jinf.2010.08.010_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2010.08.010_bib19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1056\/NEJMoa055356","article-title":"Methicillin-resistant S. aureus infections among patients in the emergency department","volume":"355","author":"Moran","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2010.08.010_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(10)70053-0","article-title":"Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe","volume":"10","author":"Otter","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2010.08.010_bib21","doi-asserted-by":"crossref","unstructured":"Putnam SD, Sader HS, Farrell DJ, Biedenbach D, Castanheira M. Antimicrobial characterization of CEM-101, a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents 2010; [Submitted for publication].","DOI":"10.1016\/j.ijantimicag.2010.08.021"},{"key":"10.1016\/j.jinf.2010.08.010_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/dkp241","article-title":"Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology","volume":"64","author":"Tenover","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445310002586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445310002586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:14:23Z","timestamp":1759007663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445310002586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0163445310002586"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2010.08.010","relation":{},"ISSN":["0163-4453"],"issn-type":[{"type":"print","value":"0163-4453"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2010.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}